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At the recent American College of Cardiology (ACC) meet-
ing in Orlando, I participated in one of the Controversies in
Cardiology sessions, regarding conflicts of interest for clin-
ical researchers. As I prepared my remarks, it became
apparent that some important changes, which I would like
to highlight in this Editor’s Page, are evolving in the
guidelines for such individuals.
Previously, I wrote an Editor’s Page entitled “Full Disclo-
sure, the Antidote to Conflict of Interest” (1). I still believe that
a full disclosure of all conflicts of interest relating to industry in
the first slide of any talk goes a long way toward defusing or
identifying bias that may creep into one’s remarks. Until this
becomes the norm, however, the listener remains unsure about
the speaker’s potential conflicts of interest, especially when
he/she is particularly laudatory of a given product.
A recent national survey of policies on disclosure of con-
flicts of interest in biomedical research (2) reviewed the
current guidelines in 127 medical schools and 170 research
institutions that receive more than $5 million from the
National Institute of Health (NIH) or the National Science
Foundation (NSF). Forty-eight journals and 17 federal
agencies were also surveyed. The results were quite inter-
esting. Five medical schools and 10 research institutions had
no policy on conflict of interest. Ninety-one percent of the
institutions that had policies adhered to the federal thresh-
old for disclosure ($10,000 in annual income or equity, or
5% ownership). Eight percent had policies requiring disclo-
sure to funding agencies; 7% had policies requiring disclo-
sure to journals; and four federal agencies had no policies on
conflicts of interest. Only 43% of the journals surveyed had
policies for disclosure of conflict of interest. Twenty-one
percent required disclosure of income and equity interests,
and only 2% required that conflicts of interest be reported.
The authors of this article made several recommendations
based on the above data. There needed to be greater
uniformity among institutional policies. All federal agencies
should adopt a common conflict-of-interest rule. Research
institutions should report to federal agencies the substance
of conflicts and strategies for managing them. Journals
should require disclosure of substantive conflicts of interest
from all authors and should publish this information routinely.
Both institutional review boards (IRBs) and research subjects
should routinely be informed about conflicts of interest.
Another recent article (3) summarized the conflict-of-
interest policies for investigators in clinical trials from the 10
medical schools in the U.S. that receive the most NIH
funding. These included (in alphabetical order) Baylor,
Columbia, Harvard, Johns Hopkins, University of Pennsyl-
vania, UCLA, UCSF, University of Washington, Washing-
ton University of St. Louis, and Yale. All 10 required faculty
members to disclose financial interests to university officials.
Only four required disclosure by all members of the research
staff. Five required disclosure of all financial interests. Six
required disclosure to an IRB and a committee on conflicts
of interest. Four had requirements that were stricter than
federal regulations for investigators conducting clinical trials.
One prohibited investigators from having stock, stock options,
consulting agreements, or decision-making positions involving
a company sponsoring the research. One prohibited researchers
from trading stock or stock options in a company that
sponsored the research or sold the product or device under
study. Two did not allow faculty members to participate in
clinical research if they had a significant financial interest in the
company owning the product or device being studied.
Based on this data, the authors recommended that
university-based investigators be prohibited from holding
stock, stock options, or decision-making positions in a
company affected by the results of their clinical research.
They noted that of the 10 medical schools surveyed, only
one had a policy that was close to this standard.
Based on this kind of information, Dean Joseph B.
Martin of Harvard Medical School convened a group of
individuals from eight of the above medical schools, plus
another group of distinguished academics, to make recom-
mendations to the Association of American Medical Col-
leges (AAMC) regarding conflict-of-interest policies for
investigators in medical schools. One of those recommen-
dations was that individuals directly involved in conducting,
designing, or reporting research involving human subjects
should have, at most, a minimal personal financial interest
in a company that sponsors the research or owns the
technology being studied. Thus, it will not be enough simply to
declare a conflict of interest, but certain investigators will be
prohibited from doing key clinical studies if they have more
than a minimal financial interest in the drug or device.
The HEART Group (Heart Editors Action Round
Table) has also been wrestling with this issue as it pertains
to journals. At the recent American Heart Association and
ACC meetings, a joint statement that will appear in each of
the journals (including JACC) in the near future was
adopted, regarding conflict-of-interest statements from au-
thors. It is clear to me that these developments may change
the face of clinical research greatly, mostly for the better. It
is unfortunate that financial conflicts of interest play such a
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potent role in the current climate of clinical research, but
recognition of this fact will help all of us to interpret the
results of scientific trials appropriately.
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